Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

Michael S. Perry, a Director at Arrowhead Pharmaceuticals, sold 11,600 of the company's common shares on August 18, 2026, according to an SEC Form 4 filing. The transaction value was estimated at $1 million based on the weighted average sale price of $87.30 per share, while the post-transaction value, using the closing price on August 18, 2026, was $87.90 per share.

The director executed the sale in multiple transactions, with prices ranging from $87.20 to $87.44 per share. This move reduced Perry's direct ownership in the company by 9%, but he still maintains a stake, holding 0.0791% of the company's equity and retaining common shares tied to unvested restricted stock units. Arrowhead Pharmaceuticals, a Pasadena-based biotechnology firm with a market capitalization of $12.2 billion, is focused on developing RNA interference-based therapies for rare genetic diseases and complex liver conditions.

The company reported $669.5 million in trailing twelve-month revenue, along with a net loss of $320 million. Despite the recent stock price surge of over 217.7% in the last year, outpacing the S&P 500's 18.8% growth, analysts remain cautious, with mixed price targets ranging from $100 to $126, representing potential gains of 15.8% to 46%.